Literature DB >> 35373081

Payment, Coverage, and Health Economics of SGLT2 Inhibitors.

Ngoc-Yen T Pham1, Christos P Argyropoulos2, Sireesha Koppula2.   

Abstract

Entities:  

Keywords:  chronic kidney disease; coverage; diabetic kidney disease; health economics; sodium glucose cotransporter two inhibitors

Mesh：

Substances：

Year:  2021        PMID： 35373081      PMCID： PMC8791368          DOI： 10.34067/KID.0000742021

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  12 in total

1.  Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.

Authors:  Apostolos Tsapas; Ioannis Avgerinos; Thomas Karagiannis; Konstantinos Malandris; Apostolos Manolopoulos; Panagiotis Andreadis; Aris Liakos; David R Matthews; Eleni Bekiari
Journal:  Ann Intern Med       Date:  2020-06-30       Impact factor: 25.391

2.  Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trial.

Authors:  Ameur M Manceur; Mike Durkin; Akshay Kharat; Brahim Bookhart; Marie-Hélène Lafeuille; Dominic Pilon; Iman Fakih; Patrick Lefebvre
Journal:  Curr Med Res Opin       Date:  2020-01-09       Impact factor: 2.580

3.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors:  Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2019-04-14       Impact factor: 91.245

4.  Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.

Authors:  William H Herman; Shahnaz Shahinfar; George W Carides; Erik J Dasbach; William C Gerth; Charles M Alexander; John R Cook; William F Keane; Barry M Brenner
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

5.  Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years.

Authors:  S Grandy; A M Langkilde; J E Sugg; S Parikh; C D Sjöström
Journal:  Int J Clin Pract       Date:  2014-02-06       Impact factor: 2.503

6.  Dapagliflozin in Patients with Chronic Kidney Disease.

Authors:  Hiddo J L Heerspink; Bergur V Stefánsson; Ricardo Correa-Rotter; Glenn M Chertow; Tom Greene; Fan-Fan Hou; Johannes F E Mann; John J V McMurray; Magnus Lindberg; Peter Rossing; C David Sjöström; Roberto D Toto; Anna-Maria Langkilde; David C Wheeler
Journal:  N Engl J Med       Date:  2020-09-24       Impact factor: 91.245

7.  Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.

Authors:  Javed Butler; Stefan D Anker; Gerasimos Filippatos; Muhammad Shahzeb Khan; João Pedro Ferreira; Stuart J Pocock; Nadia Giannetti; James L Januzzi; Ileana L Piña; Carolyn S P Lam; Piotr Ponikowski; Naveed Sattar; Subodh Verma; Martina Brueckmann; Waheed Jamal; Ola Vedin; Barbara Peil; Cordula Zeller; Faiez Zannad; Milton Packer
Journal:  Eur Heart J       Date:  2021-03-31       Impact factor: 29.983

Review 8.  The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now.

Authors:  Michael E Johansen; Christos Argyropoulos
Journal:  Clin Cardiol       Date:  2020-11-09       Impact factor: 2.882

9.  Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model.

Authors:  Michael Willis; Andreas Nilsson; Klas Kellerborg; Philip Ball; Rupert Roe; Shana Traina; Rebecca Beale; Isabelle Newell
Journal:  Diabetes Ther       Date:  2020-12-02       Impact factor: 2.945

10.  Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.

Authors:  Jing Luo; Robert Feldman; Scott D Rothenberger; Inmaculada Hernandez; Walid F Gellad
Journal:  JAMA Netw Open       Date:  2020-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.